Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Deals R&D

Nona Biosciences Partners with Dr. Michael S. Diamond for Viral Disease Monoclonal Antibody Research

Fineline Cube Apr 19, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates in the...

Company Deals

Everest Medicines and SPH Keyuan Ink MoU to Expand Xerava Distribution in China

Fineline Cube Apr 19, 2023

China-based Everest Medicines (HKG: 1952) has announced a Memorandum of Understanding (MoU) with a subsidiary...

Company Drug

Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting

Fineline Cube Apr 19, 2023

China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study...

Medical Device Policy / Regulatory

National Center Reports Increase in Medical Device Adverse Event Reports for 2022

Fineline Cube Apr 19, 2023

The National Center for Adverse Event Monitoring has released its national annual report regarding the...

Policy / Regulatory

China’s NMPA, MPS, and NHC Announce Updates to Narcotics and Psychotropic Substances Catalog

Fineline Cube Apr 19, 2023

The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...

Company Deals

China Resources Biopharmaceutical Partners with Hefei Institute and Afana Bio for Joint Lab

Fineline Cube Apr 19, 2023

China Resources Biopharmaceutical Co., Ltd has announced a strategic partnership with the Hefei Comprehensive National...

Company Drug

XZenith Biopharm Completes Enrollment in Phase II Study for Proton Pump Inhibitor

Fineline Cube Apr 19, 2023

XZenith Biopharm, a Chinese company with minority ownership by Sihuan Pharma, has completed patient enrollment...

Company Drug

Adagene Inc. Presents Positive Interim Results for ADG126 at AACR Annual Meeting

Fineline Cube Apr 19, 2023

China-based Adagene Inc. (NASDAQ: ADAG) has announced interim results from its combination dose escalation studies...

Company Drug

BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination

Fineline Cube Apr 18, 2023

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) and SpringWorks Therapeutics Inc., (NASDAQ: SWTX) have...

Company Drug

HanchorBio Receives FDA Approval for Multi-Region Clinical Study of HCB101 Fusion Protein

Fineline Cube Apr 18, 2023

Taiwan-based HanchorBio has announced receiving the green light from the US FDA to conduct a...

Company Deals

Hainan’s Boao Lecheng Partners with Sonova to Advance Hearing Health Solutions in China

Fineline Cube Apr 18, 2023

The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has struck a strategic partnership...

Company Deals

Nanjing Chamlion Laser Technology Secures RMB 236 Million in Series B Financing for Dental 3D Printing

Fineline Cube Apr 18, 2023

Nanjing Chamlion Laser Technology Co., Ltd, a leading provider of dental metal 3D printing solutions...

Company Drug

HutchMed’s Elunate Receives NMPA Review for Second-Line Gastric Cancer Treatment

Fineline Cube Apr 18, 2023

China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that the National Medical Products Administration (NMPA)...

Company Drug

HuidaGene Receives CDE IND Approval for Ophthalmology Gene Therapy HG004

Fineline Cube Apr 18, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...

Company Drug

CBMG’s C-CAR031 Shows Promising Results in Phase I Study for Hepatocellular Carcinoma

Fineline Cube Apr 18, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has published the results of the...

Company

CanSino Biologics Reports 2022 Revenue Drop and Increased Losses Amid COVID-19 Vaccine Market Shifts

Fineline Cube Apr 18, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has released its 2022 financial report, recording...

Company Deals

PackGene Secures Series C Financing to Boost AAV Innovation and Global Expansion

Fineline Cube Apr 18, 2023

China-based PackGene Biotech has announced the successful completion of a Series C financing round, securing...

Company Deals

Bioworkshops Secures RMB 100 Million in Series A Financing for Biologic Drug Development

Fineline Cube Apr 18, 2023

Bioworkshops, a Contract Development and Manufacturing Organization (CDMO) based in Suzhou and specializing in biologic...

Company Medical Device

Sinovation Medical’s SinoLITT System and Fiber Kit Gain NMPA Approval for Epilepsy Treatment

Fineline Cube Apr 18, 2023

Sinovation (Beijing) Medical Technology Co., Ltd has announced that its in-house developed magnetic resonance monitoring...

Company R&D

Merck and XtalPi Leverage Molecular Dynamics to Enhance Small-Molecule Crystallization

Fineline Cube Apr 17, 2023

German pharmaceutical giant Merck (NYSE: MRK) and China-based drug discovery solutions specialist XtalPi have published...

Posts pagination

1 … 587 588 589 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.